Efficacy of Tolvaptan on ADPKD Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-01

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigation of the therapeutic effects of tolvaptan in patients with autosomal dominant polycystic kidney disease This is a prospective 5-year study to compare the change in total kidney volume (TKV) before and after tolvaptan therapy, as the primary endpoint, in patients with ADPKD. Study results will be summarized, analyzed, and compiled into a research paper at 5 years (data cut-off, Aug 31, 2020).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy Study of Water Drinking on PKD Progression.

NCT01348035

Autosomal Dominant Polycystic Kidney Disease Disease Progression

COMPLETED

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT01430494

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

COMPLETED

Analysis of Patients With Autosomal Dominant Polycystic Kidney

NCT06759142

Autosomal Dominant Polycystic Kidney ADPKD

RECRUITING

The German ADPKD Tolvaptan Treatment Registry

NCT02497521

ADPKD (Autosomal Dominant Polycystic Kidney Disease)

RECRUITING

The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease

NCT04023214

Polycystic Kidney, Autosomal Dominant

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Based on the results of a study entitled "The Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO 3:4) 1)," tolvaptan was approved in March 2014 for the treatment of autosomal dominant polycystic Kidney Disease (ADPKD) in Japan, followed by in other regions such as Europe and Canada.

In May 2014, Kyorin University Hospital started administration of tolvaptan to patients with ADPKD. In the clinical setting in which the dosing conditions differ from those in the TEMPO study, aspects that were not addressed in the TEMPO study may be investigated. The present study is a longitudinal clinical study to investigate the changes before and after administration of tolvaptan by employing a method different from that used in the TEMPO study in patients in whom the clinical course of the disease has been monitored since prior to the approval of tolvaptan.

The observation period (for a maximum duration of 3 years) of the study was originally planned to be completed on March 31, 2018 and the analyses of study results and the preparation of a research paper until September 2019. However, the study will be extended for another 2 years, because the long-term effects of the drug should be further investigated.

The indication approved in Japan defines the target population as those with an eGFR ≥15 mL/min/1.73 m2, but not specifies the upper limit of age. Therefore, the present study will permit the assessment of therapeutic effects of the drug in patients who are older or have more severe renal impairment as compared with in those participating in the TEMPO3:4 and 4.4 studies. Since such patients generally have a greater TKV, the study may also provide information to decide whether the efficacy of tolvaptan differs according to TKV. The present study is a single-arm longitudinal study, unlike the preceding studies that were placebo-controlled studies 1,2); therefore, tolvaptan may be evaluated from different perspectives.

Rationale of DNA analysis The association between pathogenic genotype and the effects of tolvaptan has been reported, but the impact of mutation site has not been cleared 2). Genetic analysis for polycystic kidney will be included in the study to decide whether the effects of tolvaptan is associated with mutation site as well as pathogenic genotype (PKD1, PKD2).

Validation of alpha as a HtTKV slope Assuming that TKV corrected for the height at the age at measurement (t years old), HtTKVt (mL/m), increases at a constant annual rate (α, %/ per year) and the HtTKV0 is 150 mL/m, the following equation will be satisfied: HtTKVt = 150 (1+α)t. The α value calculated from the equation will be used as an indicator for supplementarily assessing the effect of tolvaptan on HtTKV slope 5,6).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autosomal Dominant Polycystic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with ADPKD

This analysis set consists of patients whose at least 2 TKV data are available both before and after taking tolvaptan.

Group Type OTHER

Tolvaptan

Intervention Type DRUG

* Before administration of tolvaptan

* TKV・Liver capacity: Once/year (an additional measurement within 3 months before start of administration)
* 24-hour urine collection・Hematology/urinalysis: Once/year
* Physical findings: Blood pressure and medical interview at ambulatory visit
* Hospitalization for education and examination at the start of tolvaptan administration

* 24-hour urine collection・Hematology/urinalysis・Inulin clearance
* Physical findings: Body weight, blood pressure
* Adverse Events
* After administration of tolvaptan

* TKV・Liver capacity・inulin clearance: Once/year
* 24-hour urine collection: Once/6 months
* Hematology/urinalysis: Once/month in principle
* Physical findings: Blood pressure and medical interview at ambulatory visit
* Adverse Events

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tolvaptan

* Before administration of tolvaptan

* TKV・Liver capacity: Once/year (an additional measurement within 3 months before start of administration)
* 24-hour urine collection・Hematology/urinalysis: Once/year
* Physical findings: Blood pressure and medical interview at ambulatory visit
* Hospitalization for education and examination at the start of tolvaptan administration

* 24-hour urine collection・Hematology/urinalysis・Inulin clearance
* Physical findings: Body weight, blood pressure
* Adverse Events
* After administration of tolvaptan

* TKV・Liver capacity・inulin clearance: Once/year
* 24-hour urine collection: Once/6 months
* Hematology/urinalysis: Once/month in principle
* Physical findings: Blood pressure and medical interview at ambulatory visit
* Adverse Events

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Samsca

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients who have started or will start receiving tolvaptan at Kyorin University Hospital.
2. Patients whose use of Samsca complies with the criteria specified by the Ministry of Health, Labour and Welfare.

* TKV ≥ 750 mL.
* The increase in total renal capacity ≥ approximately 5%/year.
3. Patients who have given signed consent to the examination protocol, which includes hospitalization at the initiation of tolvaptan treatment (i.e. examination/educational hospitalization for the first 3 days. Monthly blood tests at the time of ambulatory visits, 24-hour urine collection every 6 months, annual TKV measurement by MRI and inulin clearance measurement)
4. Patients for whom the baseline TKV and eGFR percent change is available.
5. Patients from whom freely given, written informed consent to participate in the study has been obtained.

Exclusion Criteria

1. Patients who do not consent to participation in the study, or those who later withdraw their consent.
2. Patients who have been taking tolvaptan since the TEMPO study.
3. Patients who are not eligible at our hospital to take tolvaptan for the stated indication based on the criteria for careful administration of Samsca as specified by the Ministry of Health, Labour and Welfare.

* Patients with a history of hypersensitivity to tolvaptan or similar chemical compounds.
* Patients who do not feel thirsty or have difficulty swallowing water.
* Patients with hypernatremia.
* Patients with eGFR \< 15 mL/min/1.73 m2.
* Patients with chronic hepatitis, drug-induced hepatic dysfunction and other hepatic dysfunctions.
* Pregnant women or women suspected of being pregnant. Female patients who wish to become pregnant.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No